Consumer Marketing briefs

Share this article:
An AdvaMed-Porter Novelli survey found that among device makers, 94% of DTC marketing efforts are focused on patient benefit materials such as patient brochures, with a majority of advertising campaigns in print and most ads appearing in traditional media.

A promotional card for Sanofi Aventis's overactive bladder drug Uroxatral omitted indication and risk information, and also used outdated product labeling, said DDMAC in a warning letter. Although risk and indication information was printed on the back of the card, the warning letter noted that “The tent card is designed to be adhered to a flat surface (e.g., a pharmacy counter) and as a practical matter, viewers of the front side of the card are unlikely to be able to view the back side of the card once it is stuck in place.”

The American Medical Association (AMA) partnered with the Flu Information Care System to launch a flu assessment site for consumers. The site,, will help patients determine the severity of their flu symptoms and share that information with a physician andis the first step in a larger AMA web initiative that will provide additional online tools for patients and docs.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?